On July 25, 2025, Processa Pharmaceuticals, Inc. filed a prospectus supplement allowing the sale of $5,239,073 worth of common stock under an equity agreement, having already sold $1,546,338 in the past 12 months, leaving $3,692,735 available for future sales.